Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats

Prasath, Gopalan Sriram; Pillai, S. Iyyam; Subramanian, S.

doi:10.1016/j.ejphar.2014.06.065

Cited by 82 publications

(45 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fisetin has a plasma terminal half-life of just over 3 hours in mice, with its metabolites being excreted in feces and urine. It alleviates dysfunction in animal models of chronic disease, including diabetic kidney disease and acute kidney injury [19, 20, 27-29], attributes consistent with those expected from a senolytic agent [9]. Here we demonstrate that fisetin is indeed senolytic in senescent HUVECs, but not in senescent IMR-90 cells or human preadipocytes.…”

Section: Discussionsupporting

confidence: 78%

“…Due to it's being hydrophobic, fisetin penetrates cell membranes and accumulates within cells to exert antioxidant effects [18]. Other promising biological activities of fisetin include anti-hyperglycemic, anti-hyperlipidemic, anti-inflammatory, neurotrophic, and anti-carcinogenic effects [16, 19-26]. Fisetin promotes apoptosis in human breast cancer MCF-7 cells by activating caspases-7,8,&9 without causing apoptosis in non-tumorigenic cells [25].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

Zhu

Doornebal

Pirtskhalava

et al. 2017

Aging

551

385

View full text Add to dashboard Cite

Senescent cells accumulate with aging and at sites of pathology in multiple chronic diseases. Senolytics are drugs that selectively promote apoptosis of senescent cells by temporarily disabling the pro-survival pathways that enable senescent cells to resist the pro-apoptotic, pro-inflammatory factors that they themselves secrete. Reducing senescent cell burden by genetic approaches or by administering senolytics delays or alleviates multiple age- and disease-related adverse phenotypes in preclinical models. Reported senolytics include dasatinib, quercetin, navitoclax (ABT263), and piperlongumine. Here we report that fisetin, a naturally-occurring flavone with low toxicity, and A1331852 and A1155463, selective BCL-XL inhibitors that may have less hematological toxicity than the less specific BCL-2 family inhibitor navitoclax, are senolytic. Fisetin selectively induces apoptosis in senescent but not proliferating human umbilical vein endothelial cells (HUVECs). It is not senolytic in senescent IMR90 cells, a human lung fibroblast strain, or primary human preadipocytes. A1331852 and A1155463 are senolytic in HUVECs and IMR90 cells, but not preadipocytes. These agents may be better candidates for eventual translation into clinical interventions than some existing senolytics, such as navitoclax, which is associated with hematological toxicity.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

Zhu

Doornebal

Pirtskhalava

et al. 2017

Aging

551

385

View full text Add to dashboard Cite

show abstract

“…More recently, FS supplementation has been reported to decrease cardiovascular risks [9] and downregulate both glycogenolysis and gluconeogenesis in vitro [10][11][12], mainly attributed to its antioxidant capacities.…”

Section: Introductionmentioning

confidence: 99%

Nanoencapsulation of dietary flavonoid fisetin: Formulation and in vitro antioxidant and α-glucosidase inhibition activities

Sechi

Syed

Pala

et al. 2016

Materials Science and Engineering: C

View full text Add to dashboard Cite

“…Fisetin (3,3',4',7-tetrahydroxyflavone) (Scheme-1), one of the flavonols, is found in eudicotyledons, vegetables, fruits, herbal and drinks. 8,9 Fisetin is a potent sirtuin-activating 25 compound, 10 an agent that modulates sirtuins and plays important roles in anti-aging, anti-inflammatory, anti-prostate cancer, inhibiting human melanoma, 10-13 eutherapeutic for pancreatitis and diabetics 14 . Fisetin can also enhance the memory and may be good for treating memory disorders.…”

Section: Introductionmentioning

confidence: 99%

Fluorescence enhancement of fisetin by silver nanoparticles with cetyltrimethyl ammonium bromide micelles

Liu

2015

RSC Adv.

View full text Add to dashboard Cite

The synergies action of solubilization and sensitization of micelles and the metal-enhanced fluorescence of AgNPs enhance fluorescence of Fisetin. AbstractIn this paper, in situ synthesized cetyltrimethyl ammonium bromide micelles-capped silver nanoparticles were used to sensitively and directly detect Fisetin. Fisetin molecules solubilize in Stern layer of cetyltrimethyl ammonium bromide micelles and mainly bind to the head group of the micelles by electrostatic interaction and hydrophobic effect. Silver nanoparticles also solubilize in cetyltrimethyl 10 ammonium bromide micelles and form the micelles-capped silver nanoparticles. The suitable distances between Fisetin molecules and silver nanoparticles for the fluorescence enhancement are provided by the micelles. The synergies action of the solubilization and sensitization of micelles and metal-enhanced fluorescence of silver nanoparticles promote the fluorescence enhancement of the system. Under optimized conditions, the fluorescence intensity of the system exhibits a linear response with the 15 concentrations of Fisetin in range from 5.0×10 -8 moL L -1 to 7.0×10 -6 moL L -1 and the detection limit (S/N = 3) is 1.5×10 -9 moL L -1 . Compared to the other methods, the developed method has higher sensitivity. And the method has been successfully used to detect Fisetin in actual samples.

show abstract

Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats

Cited by 82 publications

References 44 publications

New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

Nanoencapsulation of dietary flavonoid fisetin: Formulation and in vitro antioxidant and α-glucosidase inhibition activities

Fluorescence enhancement of fisetin by silver nanoparticles with cetyltrimethyl ammonium bromide micelles

Contact Info

Product

Resources

About